DOI: 10.1002/prp2.1244

COMMENTARY



Has the human biological interaction with SARS-CoV2 variants entered a pliant "Faustian bargain"?

Richard J. Head¹ | Marko Popovic² | Jennifer H. Martin³

¹Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia

²Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Belgrade, Serbia

³Centre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia

Correspondence

Jennifer H. Martin, Clinical Pharmacologist, University of Newcastle School of Medicine, Kookaburra Circuit, New Lambton Heights 2305, New South Wales, Australia. Email: jenniferh.martin@newcastle.edu.au

Abstract

We hypothesize that a "Faustian bargain"—the trading of increased SARS—CoV2 viral infection with a concurrent potential for prevention of life-threatening lower lung infection explains the previous and future morbidity and mortality from COVID-19. Further, this trade-off is made feasible by fundamental principles of thermodynamics and receptor affinity.

KEYWORDS COVID-19, Gibbs free energy, thermodynamics

We have highlighted recently¹ the importance of the affinity of SARS-CoV2 for its target the Angtiontensin II (ACEII) receptor, and in fundamental thermodynamic terms, this affinity is linked to the passage of the virus from the airway and its subsequent diffusion across the mucosa. This relationship of infectivity and pathophysiology in the upper airway is key to understanding the morbidity and mortality of this pandemic. For example, the dissociation constant, Kd, of SARS-CoV is 5.0 nM, while that of SARS-CoV-2 is 1.2 nM, at 30°C.² These values can be used to find Gibbs energy of binding, which is: $\Delta_B G^0 = -48.2 \text{ kJ/mol}$ for SARS-CoV and $\Delta_B G^0 = -51.8 \text{ kJ/mol}$ for SARS-CoV-2. Thus, SARS-CoV-2 has a 1.075 × greater binding affinity than SARS-CoV.

With a high affinity of SARS-CoV2 for the ACEII receptor in the nasopharyngeal region, the virus will be drawn from the upper airway, leading to a relatively survivable upper airway respiratory infection. In contrast with lower affinity SARS-CoV2 mutants, there will be poorer upper airway viral extraction and a higher risk of viral migration to the lower lung, with potentially life-threatening consequences, as seen early on in the pandemic. Thus, as the affinity increases with SARS-CoV2 variants, the resultant upper airway infection favors both viral spread in the population as well as engendering a greater potential for population survival. For completeness, the binding affinities for the SARS-CoV-2 variants can be found in [4].

There is thus a convergent and common opportunity for the virus and for human, that is, a modified "Faustian bargain" based upon a convergent and shared advantage.³ Indeed, an analysis of the appearance of mutations through time evolution of SARS-CoV-2 from Hu-1 to the latest XBB.1.9.1 and XBB.1.16 variants shows a decrease in Gibbs energy of binding, equivalent to increase in affinity, increasing antigen-receptor binding, virus passage through the mucosa, and increased infectivity.⁴⁻⁶

The "Faustian bargain" is thus the trading of the possibility of increased viral infection in the population with a concurrent potential for prevention of life-threatening lower lung infection made feasible by the fundamental principles of thermodynamics.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2024} The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

AUTHOR CONTRIBUTIONS

The original idea is from RIchard Head. All authors contributed to the development of the hypothesis, analysis and writing of the article.

ACKNOWLEDGMENTS

Nil.

DATA AVAILABILITY STATEMENT

Not applicable.

ETHICS STATEMENT

Not applicable.

ORCID

Richard J. Head ⁽¹⁾ https://orcid.org/0000-0002-1196-0926 Marko Popovic ⁽¹⁾ https://orcid.org/0000-0003-0934-5550 Jennifer H. Martin ⁽¹⁾ https://orcid.org/0000-0002-8614-0199

REFERENCES

 Popovic M, Martin J, Head R. COVID infection in 4 steps: thermodynamic considerations reveal how viral mucosal diffusion, target receptor affinity and furin cleavage act in concert to drive the nature and degree of infection in human COVID-19 disease. *Heliyon*. 2023;9(6):e17174. doi:10.1016/j.heliyon.2023.e17174

- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell.* 2020;181(2):281-292.e6. doi:10.1016/j. cell.2020.02.058
- 3. https://www.britannica.com/topic/Faustian-bargain
- Popovic M. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of omicron BQ.1, BQ.1.1, XBB and XBB.1 variants. *Microb Risk Anal.* 2023;23:100250. doi:10.1016/j.mran.2023.100250
- Popovic M, Pavlović M, Pavlović M. Ghosts of the past: elemental composition, biosynthesis reactions and thermodynamic properties of zeta P.2, eta B.1.525, theta P.3, kappa B.1.617.1, iota B.1.526, lambda C.37 and mu B.1.621 variants of SARS-CoV-2. *Microbial Risk Anal.* 2023;24:100263. doi:10.1016/j.mran.2023.100263
- Popovic ME. XBB.1.5 kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2. *Microbiol Res.* 2023;270:127337. doi:10.1016/j.micres.2023.127337

How to cite this article: Head RJ, Popovic M, Martin JH. Has the human biological interaction with SARS-CoV2 variants entered a pliant "Faustian bargain"? *Pharmacol Res Perspect*. 2024;12:e1244. doi:10.1002/prp2.1244